News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Intra-Cellular Therapies, Inc. Presents New Data From The Phase 2 Clinical Trial Of ITI-007 In Schizophrenia At The 167th Annual Meeting Of The American Psychiatric Association


5/7/2014 9:13:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, May 6, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders is presenting additional data from the Phase 2 clinical trial of ITI-007 in schizophrenia at the 167th Annual Meeting of the American Psychiatric Association (APA) being held in New York, NY.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES